Servier to Acquire Agios Pharmaceuticals' Oncology Business
Paris and Boston (ots/PRNewswire) - - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug ...
mehr